BRPI0916689A2 - composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida. - Google Patents

composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.

Info

Publication number
BRPI0916689A2
BRPI0916689A2 BRPI0916689A BRPI0916689A BRPI0916689A2 BR PI0916689 A2 BRPI0916689 A2 BR PI0916689A2 BR PI0916689 A BRPI0916689 A BR PI0916689A BR PI0916689 A BRPI0916689 A BR PI0916689A BR PI0916689 A2 BRPI0916689 A2 BR PI0916689A2
Authority
BR
Brazil
Prior art keywords
stabilizing
pharmaceutical composition
solid preparation
methods
stabilized
Prior art date
Application number
BRPI0916689A
Other languages
English (en)
Inventor
Muneo Nonomura
Yasuhiro Hiraishi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41327301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0916689(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI0916689A2 publication Critical patent/BRPI0916689A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
BRPI0916689A 2008-07-28 2009-07-27 composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida. BRPI0916689A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008194219 2008-07-28
PCT/JP2009/063708 WO2010013823A2 (en) 2008-07-28 2009-07-27 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
BRPI0916689A2 true BRPI0916689A2 (pt) 2015-11-17

Family

ID=41327301

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916689A BRPI0916689A2 (pt) 2008-07-28 2009-07-27 composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.

Country Status (29)

Country Link
US (2) US9186411B2 (pt)
EP (2) EP2564833B1 (pt)
JP (2) JP5295356B2 (pt)
KR (1) KR20110042334A (pt)
CN (3) CN102743330B (pt)
AR (1) AR072842A1 (pt)
AU (1) AU2009277443A1 (pt)
BR (1) BRPI0916689A2 (pt)
CA (2) CA2732243C (pt)
CL (1) CL2011000170A1 (pt)
CO (1) CO6290638A2 (pt)
CR (1) CR20110110A (pt)
DO (2) DOP2011000033A (pt)
EA (2) EA201170272A1 (pt)
EC (1) ECSP11010855A (pt)
ES (2) ES2669592T3 (pt)
GE (2) GEP20146122B (pt)
IL (2) IL210735A0 (pt)
MA (1) MA32556B1 (pt)
MX (1) MX2011000757A (pt)
MY (2) MY156305A (pt)
NZ (2) NZ591344A (pt)
PE (3) PE20141585A1 (pt)
SG (1) SG186685A1 (pt)
TW (2) TW201010992A (pt)
UA (1) UA103332C2 (pt)
UY (1) UY32008A (pt)
WO (1) WO2010013823A2 (pt)
ZA (1) ZA201101198B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013122260A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
AR091567A1 (es) * 2012-06-27 2015-02-11 Takeda Pharmaceutical Preparacion liquida, metodo, kit de inyeccion
HUE032635T2 (en) 2012-09-19 2017-10-30 Taiho Pharmaceutical Co Ltd For oral administration of pharmaceutical compositions having improved elution and / or absorbance
EP2968695A1 (en) * 2013-03-14 2016-01-20 Allergan, Inc. Polymer system for securing implants in syringe needles
CN105330647A (zh) * 2014-08-14 2016-02-17 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
CN105985278A (zh) * 2015-01-27 2016-10-05 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
MA41850A (fr) 2015-03-31 2018-02-06 Takeda Pharmaceuticals Co Nouvelles utilisations pharmaceutiques
US10835541B2 (en) 2015-07-30 2020-11-17 Takeda Pharmaceutical Company Limited Tablet
CN105106203B (zh) * 2015-08-17 2019-04-05 江苏豪森药业集团有限公司 富马酸沃诺拉赞的药物组合物及其制备方法
CN105030725B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶组合物及其制备方法
CN105030720B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶片及其制备方法
CN107224438B (zh) * 2016-03-25 2021-04-06 江苏豪森药业集团有限公司 富马酸沃诺拉赞药物组合物
US11331316B2 (en) * 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
CN106580903B (zh) * 2016-11-17 2019-12-13 江苏豪森药业集团有限公司 罗红霉素缓释药物组合物
CN106860852A (zh) * 2017-02-17 2017-06-20 王清华 一种用于结合治疗胃病的粘液西药
MX2019014201A (es) 2017-05-31 2020-01-23 Boehringer Ingelheim Int Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas.
CA3069563A1 (en) 2017-07-10 2019-01-17 Takeda Pharmaceutical Company Limited Preparation comprising vonoprazan
CN108558831B (zh) * 2018-06-08 2021-07-27 上海璃道医药科技有限公司 取代吡咯-4-烷基胺类化合物及其用途
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
CN109288722B (zh) * 2018-11-09 2021-03-30 伯德创研(广州)生物科技有限公司 一种变色修正肤色的粉底及其制备方法
CN110538153B (zh) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 一种高稳定性、快速释放的固体制剂及其制备方法
PH12022552791A1 (en) * 2020-04-24 2024-03-25 Dr Falk Pharma Gmbh Systemic Formulation of a Pyridinone Derivate for Coeliac Disease
CN111973565A (zh) * 2020-07-07 2020-11-24 南京海纳医药科技股份有限公司 一种含有富马酸沃诺拉赞的片剂及其溶出度测定方法
CN114053239A (zh) * 2020-08-01 2022-02-18 吉林汇康制药有限公司 一种富马酸伏诺拉生药物组合物及制备方法
CN111943932B (zh) * 2020-08-06 2023-07-14 四川国康药业有限公司 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途
JP2023544327A (ja) * 2020-10-01 2023-10-23 イマーゴ バイオサイエンシーズ インコーポレイテッド Ｋｄｍ１ａによって媒介される疾患を治療するための医薬製剤
CN114853728B (zh) * 2022-05-07 2023-11-07 四川制药制剂有限公司 一种富马酸伏诺拉生片及其制备方法
CN115364065B (zh) * 2022-08-23 2024-03-15 宁波高新区美诺华医药创新研究院有限公司 富马酸伏诺拉生片
CN115944743B (zh) * 2023-01-18 2025-08-08 山东诚成医药科技有限公司 一种富马酸伏诺拉生组合物及其制备方法
WO2025064381A1 (en) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Method for preparing vonoprazan with reduced nitrosamine
CN119970680B (zh) * 2023-11-10 2025-10-03 中国人民解放军军事科学院军事医学研究院 一种秋水仙碱缓释微丸及其制备方法
CN117462507B (zh) * 2023-12-28 2024-03-15 山东齐都药业有限公司 富马酸伏诺拉生药物组合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2844351B2 (ja) 1989-07-13 1999-01-06 株式会社科薬 安定なポリミキシン系抗生物質水性溶液
US5422362A (en) 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
FR2745500B1 (fr) 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
US5834503A (en) 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
FR2752162B1 (fr) 1996-08-07 1998-11-06 Jouveinal Lab Comprime de maleate de trimebutine pellicule
JP4730985B2 (ja) 1997-09-10 2011-07-20 武田薬品工業株式会社 安定化された医薬製剤
EP0901787B1 (en) * 1997-09-10 2003-05-28 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
DE60125026T2 (de) 2000-03-23 2007-06-28 Takeda Pharmaceutical Co. Ltd. Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
WO2003011296A1 (fr) * 2001-07-30 2003-02-13 Mitsubishi Pharma Corporation Preparations pharmaceutiques stables contenant comme principe actif des derives de l'acide aminobenzenesulphonique
US20040258741A1 (en) 2001-10-17 2004-12-23 Takaaki Terahara Percutaneous absorption preparations
US7247702B2 (en) * 2002-02-28 2007-07-24 The Penn State Research Foundation Periocular drug delivery for diabetic retinopathy
ES2380704T3 (es) 2002-03-07 2012-05-17 Boehringer Ingelheim International Gmbh Metanosulfonato de éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino--imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carb3onil)-piridin-2-il-amino]-propiónico
US6818662B2 (en) 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
DE10233108A1 (de) * 2002-07-20 2004-01-29 Krewel Meuselbach Gmbh Retardiertes Schmerzmittel enthaltend Tilidin und ein Lichtschutzmittel
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
TWI398273B (zh) 2003-07-18 2013-06-11 Santarus Inc 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
JP2005263788A (ja) * 2004-02-17 2005-09-29 Sankyo Co Ltd インドリン化合物を含有する安定化された医薬組成物
WO2005094812A1 (ja) * 2004-04-01 2005-10-13 Ajinomoto Co., Inc. ナテグリニド含有製剤
JP2006001912A (ja) 2004-06-21 2006-01-05 Chugai Pharmaceut Co Ltd タンパク質製剤の安定化方法
KR101178747B1 (ko) 2004-09-30 2012-09-03 다케다 야쿠힌 고교 가부시키가이샤 프로톤 펌프 저해제
CA2582300A1 (en) 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
JP5188181B2 (ja) * 2005-08-25 2013-04-24 協和発酵バイオ株式会社 血中アルコール濃度上昇抑制用組成物
HRP20110473T1 (hr) * 2005-08-30 2011-07-31 Takeda Pharmaceutical Company Limited Supstituirani derivati 1-heterociklilsulfonil, 2-aminometil, 5-(hetero)-aril 1-h-pirola kao inhibitori kiselinske sekrecije
US20090104264A1 (en) * 2005-12-28 2009-04-23 Takeda Pharmaceutical Company Limited Controlled release solid preparation
JP5365777B2 (ja) * 2006-09-15 2013-12-11 アステラス製薬株式会社 光に対して安定なラモセトロンの固形医薬組成物
JP5074052B2 (ja) 2007-02-13 2012-11-14 有限会社愛和ライト 遊技機
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
EP2190822B1 (en) 2007-09-28 2014-12-31 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compounds as proton pump inhibitors
KR101559597B1 (ko) 2007-09-28 2015-10-12 다케다 야쿠힌 고교 가부시키가이샤 ５―원 헤테로시클릭 화합물
JPWO2009066746A1 (ja) 2007-11-22 2011-04-07 国立大学法人 東京大学 組織癒着防止材および関節拘縮防止材

Also Published As

Publication number Publication date
ECSP11010855A (es) 2011-03-31
DOP2013000172A (es) 2013-11-15
EP2564833A1 (en) 2013-03-06
MY156305A (en) 2016-01-29
WO2010013823A3 (en) 2010-04-15
JP5593363B2 (ja) 2014-09-24
CA2732243C (en) 2016-11-29
EP2309985A2 (en) 2011-04-20
UA103332C2 (ru) 2013-10-10
ES2669592T3 (es) 2018-05-28
CN102743330B (zh) 2016-03-23
CR20110110A (es) 2011-04-28
NZ602592A (en) 2014-01-31
DOP2011000033A (es) 2011-04-15
EP2309985B1 (en) 2018-03-14
EA201170272A1 (ru) 2011-10-31
CA2936400A1 (en) 2010-02-04
JP5295356B2 (ja) 2013-09-18
SG186685A1 (en) 2013-01-30
AU2009277443A1 (en) 2010-02-04
IL210735A0 (en) 2011-03-31
KR20110042334A (ko) 2011-04-26
US20130261156A1 (en) 2013-10-03
CN104784180A (zh) 2015-07-22
TW201431552A (zh) 2014-08-16
PE20141585A1 (es) 2014-11-13
WO2010013823A2 (en) 2010-02-04
MX2011000757A (es) 2011-02-24
ZA201101198B (en) 2012-05-30
MY169461A (en) 2019-04-11
EA201201451A1 (ru) 2013-07-30
PE20140977A1 (es) 2014-08-20
CA2936400C (en) 2018-03-27
NZ591344A (en) 2013-03-28
CN102743330A (zh) 2012-10-24
JP2011529445A (ja) 2011-12-08
CN102164581A (zh) 2011-08-24
UY32008A (es) 2010-02-26
IL228817A0 (en) 2013-12-31
GEP20146122B (en) 2014-07-25
PE20110591A1 (es) 2011-09-15
JP2013047239A (ja) 2013-03-07
TW201010992A (en) 2010-03-16
MA32556B1 (fr) 2011-08-01
US20110124687A1 (en) 2011-05-26
EP2564833B1 (en) 2017-12-20
CO6290638A2 (es) 2011-06-20
CA2732243A1 (en) 2010-02-04
ES2660962T3 (es) 2018-03-26
GEP20146166B (en) 2014-09-25
AR072842A1 (es) 2010-09-22
CL2011000170A1 (es) 2011-06-10
US9186411B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
BRPI0916689A2 (pt) composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
BRPI0814299A2 (pt) Preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida
BRPI1012892A2 (pt) composto, e, composição farmacêutica.
BRPI1016132A2 (pt) composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável.
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI0909691A8 (pt) composto, método para preparar um composto, e, composição farmacêutica
BRPI0908092A2 (pt) Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante
BR112012000623A2 (pt) composição de emulsão estabilizada, método, e, método para preparar uma composição de emulsão estabilizada
BR112012009609A2 (pt) método para fabricar uma dispersão sólida, dispersão sólida , preparação farmacêutica e composições
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
BR112012000968A2 (pt) composto, composição e método para inibir uma fosfatidil inositol-3 cinase.
BRPI0812354A2 (pt) Composição farmacêutica não-aquosa.
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
BRPI0922566A2 (pt) polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
BRPI0910072A2 (pt) composto, composição farmaceutic, e, método para prover anestesia a um mamífero.
BRPI0809661A2 (pt) Composição farmacêutica estabilizada contendo pregabalina
BRPI0810710A2 (pt) Método para estabilização de uma proteína.
BRPI0818483A2 (pt) Método para preparar uma composição farmacêutica, composição farmacêutica, e, uso da mesma.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2376 DE 19-07-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.